Janssen Pharms Company Profile

What is the competitive landscape for JANSSEN PHARMS

JANSSEN PHARMS has fifty-seven approved drugs.

There are twenty-three US patents protecting JANSSEN PHARMS drugs.

There are six hundred and twenty-four patent family members on JANSSEN PHARMS drugs in sixty-two countries and ninety-one supplementary protection certificates in eighteen countries.

Summary for Janssen Pharms

International Patents:	624
US Patents:	23
Tradenames:	56
Ingredients:	34
NDAs:	57

Drugs and US Patents for Janssen Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-002	Jul 31, 2009	AB	RX	Yes	No	9,439,906
Janssen Pharms	LEVAQUIN	levofloxacin	TABLET;ORAL	020634-003	Sep 8, 2000		DISCN	Yes	No
Janssen Pharms	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	020635-005	Dec 20, 1996		DISCN	Yes	No
Janssen Pharms	TYLENOL W/ CODEINE NO. 3	acetaminophen; codeine phosphate	TABLET;ORAL	085055-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Pharms	ULTRAM	tramadol hydrochloride	TABLET;ORAL	020281-001	Mar 3, 1995		DISCN	Yes	No

Expired US Patents for Janssen Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	DITROPAN XL	oxybutynin chloride	TABLET, EXTENDED RELEASE;ORAL	020897-003	Jun 22, 1999	4,612,008*PED
Janssen Pharms	INVEGA SUSTENNA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	022264-004	Jul 31, 2009	5,254,556*PED
Janssen Pharms	INVEGA TRINZA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-003	May 18, 2015	6,077,843*PED
Janssen Pharms	ORTHO TRI-CYCLEN	ethinyl estradiol; norgestimate	TABLET;ORAL-21	019697-002	Jul 3, 1992	4,616,006
Janssen Pharms	ORTHO TRI-CYCLEN LO	ethinyl estradiol; norgestimate	TABLET;ORAL-28	021241-001	Aug 22, 2002	4,616,006*PED

Paragraph IV (Patent) Challenges for JANSSEN PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Oral Solution	25 mg/mL		2009-07-30
	Orally Disintegrating Tablets	0.25 mg		2005-04-11
	Extended-release Injectable Suspension	39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL		2017-11-21
	Extended-release Tablets	18 mg*, 27 mg, 36 mg and 54 mg		2005-07-19
	Tablets	50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg		2017-03-29
	Extended-release Capsules	16 mg and 24 mg		2006-03-11
	Tablets	25 mg, 100 mg and 200 mg		2001-12-26
	Capsules	15 mg and 25 mg		2005-09-07
	Tablets	10 mg, 15 mg, and 20 mg		2015-07-01
	Tablets	4 mg, 8 mg and 12 mg		2005-02-28
	Orally Disintegrating Tablets	3 mg and 4 mg		2005-03-23
	Extended-release Tablets	18 mg, 27 mg, 36 mg and 54 mg		2005-07-19
	Tablets	6.25 mg and 12.5 mg		2005-12-08
	Extended-release Capsules	8 mg		2006-03-02
	Tablets	100 mg and 300 mg		2017-03-29
	Oral Solution	10 mg/mL		2013-05-03
	Tablets	50 mg		2005-09-08
	Transdermal System	0.15 mg/0.02 mg per 24 hours		2007-03-22

International Patents for Janssen Pharms Drugs

Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	010655
Japan	6227406
Japan	4496174
Russian Federation	2379036
South Korea	102217616

Supplementary Protection Certificates for Janssen Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1827461	2018C/010	Belgium		PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824
1651658	C300670	Netherlands		PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
1608344	LUC00065	Luxembourg		PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824
1651658	PA2014008,C1651658	Lithuania		PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115
0904081	SPC/GB11/044	United Kingdom		PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Janssen Biotech
• Janssen Pharma
• Janssen Pharms
• Janssen Prods
• Janssen R And D

Pharmaceutical Competitive Landscape Analysis: Janssen Pharms – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has established itself as a formidable player. This comprehensive analysis delves into Janssen's market position, strengths, and strategic insights, offering a detailed look at how the company navigates the competitive landscape.

Janssen's Market Position

Janssen Pharmaceuticals holds a strong position in the global pharmaceutical market. As part of Johnson & Johnson, it benefits from the parent company's robust infrastructure and resources. In 2022, Janssen ranked 4th in the Pharma 50 report of largest pharmaceutical companies[6]. This ranking underscores the company's significant market presence and influence in the industry.

Global Market Share

Janssen's pharmaceutical sales in Canada account for a 2.2% share of the global market, positioning Canada as the 8th largest world market[1]. This statistic highlights the company's global reach and its ability to penetrate diverse markets.

Leading Products

Janssen's market position is bolstered by its portfolio of leading products. Some of its top-performing drugs include:

1. Stelara: An autoimmune treatment with sales of $821 million and 19.5% growth in 2022[1].
2. Remicade: An anti-arthritic drug with sales of $920 million, despite a 17.9% decline[1].
3. Darzalex and Erleada: Oncology drugs showing strong sales performance[6].

These products demonstrate Janssen's strength in key therapeutic areas such as immunology and oncology.

Janssen's Strengths

Janssen's competitive edge stems from several key strengths that set it apart in the pharmaceutical landscape.

Research and Development Focus

One of Janssen's primary strengths lies in its commitment to research and development (R&D). In 2021, Johnson & Johnson invested $11.9 billion in R&D, a 24% increase from the previous year[4]. This substantial investment underscores the company's dedication to innovation and developing cutting-edge treatments.

"The company spent $11.9 billion on R&D in 2021, a 24% increase over the previous year," - Tom Cavanaugh, Janssen's company group chairman, global commercial strategy organization[4].

Diverse Therapeutic Areas

Janssen's focus spans six core therapeutic areas, allowing it to address a wide range of medical needs:

1. Immunology
2. Infectious Diseases
3. Neuroscience
4. Oncology
5. Cardiovascular and Metabolism
6. Pulmonary Hypertension

This diversification helps mitigate risks associated with market fluctuations in any single therapeutic area.

Strategic Partnerships

Janssen has a strong track record of successful partnerships and collaborations. These alliances have led to the development of some of their most important products, such as Darzalex and Xarelto[2]. The company's ability to leverage external expertise and resources through strategic partnerships enhances its competitive position.

Innovative Approach to Drug Development

Janssen employs a pathway-based approach to drug development, which allows for more targeted and efficient research. This approach has led to significant pivots in their strategy, including:

1. Moving from immunosuppression to immune homeostasis
2. Expanding from six anatomy-based diseases to over 20 addressable diseases[4]

This innovative approach positions Janssen to address a broader range of medical needs more effectively.

Strategic Insights

Janssen's strategic decisions and future outlook provide valuable insights into its competitive positioning and growth potential.

Focus on Biopharmaceuticals

Janssen is heavily invested in biopharmaceuticals, with a robust pipeline of more than 800 new medicines, treatments, and cures[3]. This focus on biologics and innovative therapies aligns with industry trends and positions the company for future growth.

Digital Transformation

The company is embracing digital technologies to enhance its operations. Investments in data science and digital business enablement are preparing Janssen for a more technologically advanced future[7]. This digital transformation extends to areas such as remote clinical trials and automated patient recruitment, improving efficiency and expanding research capabilities.

Global Expansion Strategy

Janssen is actively pursuing global expansion opportunities to reach a wider patient population[5]. This strategy not only increases market share but also allows the company to address unmet medical needs in diverse geographical regions.

Emphasis on Precision Medicine

Janssen is investing in precision medicine, leveraging genomics, biotherapeutics, biomarkers, and molecular diagnostics[9]. This approach allows for more targeted and effective treatments, potentially improving patient outcomes and differentiating Janssen's offerings in the market.

Competitive Landscape

To fully understand Janssen's position, it's crucial to examine the broader competitive landscape.

Top Competitors

In the Canadian market, Janssen faces competition from several major pharmaceutical companies:

1. Johnson & Johnson (Janssen's parent company): 12.2% market share
2. Merck: 4.6% market share
3. Novartis: 4.5% market share
4. AbbVie: 4.4% market share
5. Novo Nordisk: 4.2% market share[1]

This competitive environment underscores the importance of Janssen's strategic initiatives and innovative approaches to maintain and grow its market position.

Industry Trends

Several key trends are shaping the pharmaceutical industry:

1. Increasing focus on rare diseases and personalized medicine
2. Growing importance of biologics and biosimilars
3. Rising healthcare costs and pressure for pricing transparency
4. Expanding use of artificial intelligence and machine learning in drug discovery
5. Shift towards value-based healthcare models

Janssen's strategies, such as its focus on biopharmaceuticals and precision medicine, align well with these industry trends.

Future Outlook

Janssen's future outlook appears promising, with several factors contributing to its potential for continued growth and success.

Growth Projections

Janssen aims to achieve $60 billion in pharmaceutical sales by 2025[6]. This ambitious goal reflects the company's confidence in its pipeline and strategic initiatives.

Pipeline Strength

With over 800 new medicines in development[3], Janssen's robust pipeline positions it well for future growth. The diversity of this pipeline across multiple therapeutic areas provides multiple avenues for potential success.

Strategic Acquisitions

Janssen's parent company, Johnson & Johnson, has demonstrated a willingness to make strategic acquisitions to enhance its capabilities. The $6.5 billion acquisition of Momenta Pharmaceuticals in 2020 is a prime example of this strategy[4].

Key Takeaways

1. Janssen Pharmaceuticals holds a strong market position, ranking 4th among global pharmaceutical companies.
2. The company's strengths include a robust R&D focus, diverse therapeutic areas, strategic partnerships, and innovative drug development approaches.
3. Janssen's strategic insights encompass a focus on biopharmaceuticals, digital transformation, global expansion, and precision medicine.
4. The competitive landscape is intense, with several major players vying for market share.
5. Janssen's future outlook is promising, with ambitious growth projections, a strong pipeline, and a strategy aligned with key industry trends.

FAQs

1. Q: What is Janssen's most successful product? A: Based on the provided data, Ozempic, a glycemic control medication, was Janssen's top-selling product with sales of $1,044 million and 84% growth in 2022.

2. Q: How does Janssen's R&D investment compare to its competitors? A: While specific comparisons aren't provided, Janssen's parent company Johnson & Johnson invested $11.9 billion in R&D in 2021, a 24% increase from the previous year, indicating a strong commitment to research and development.

3. Q: What are Janssen's key therapeutic areas? A: Janssen focuses on six core therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension.

4. Q: How is Janssen adapting to digital transformation in the pharmaceutical industry? A: Janssen is investing in data science and digital business enablement, including remote clinical trials and automated patient recruitment, to prepare for a more technologically advanced future.

5. Q: What is Janssen's approach to precision medicine? A: Janssen is investing in precision medicine by leveraging genomics, biotherapeutics, biomarkers, and molecular diagnostics to develop more targeted and effective treatments.

Sources cited: [1] https://ised-isde.canada.ca/site/canadian-life-science-industries/en/biopharmaceuticals-and-pharmaceuticals/pharmaceutical-industry-profile [2] https://www.fiercebiotech.com/sponsored/janssens-approach-business-development-and-strategic-partnerships [3] https://transparencyreport.janssen.com/2022 [4] https://www.drugdiscoverytrends.com/janssen-company-group-chairman-dishes-on-growth-strategy/ [5] https://canvasbusinessmodel.com/blogs/competitors/alys-pharmaceuticals-competitive-landscape [6] https://www.drugdiscoverytrends.com/2023-pharma50/janssen-johnson-johnsons-pharmaceutical-segment/ [7] https://digitalcommons.unl.edu/cgi/viewcontent.cgi?article=1641&context=honorstheses [9] https://innovativemedicine.jnj.com/latvia/innovation/r-d-at-janssen